{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:33:05Z","timestamp":1761989585104,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In immunocompromised patients, EBV may elicit B-cell transformation and proliferation. A 5-year-old microcephalic boy was admitted with fever and non-malignant polymorphic T-cell lymphoproliferative disease associated with EBV. A presumptive diagnosis of primary immunodeficiency with inability to control EBV was made and next-generation sequencing led to the identification of a novel ZBTB24 mutation (ICF2-syndrome). This case shows that susceptibility to EBV seems to be particular of ICF-2 as it has not been described in the other types of ICF. It is mandatory to raise the hypothesis of an underlying PID in case of severe EBV infection.<\/jats:p>","DOI":"10.3389\/fimmu.2021.654167","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T06:50:53Z","timestamp":1619592653000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Primary Immunodeficiencies, Massive EBV+ T-Cell Lympoproliferation Leading to the Diagnosis of ICF2 Syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Gon\u00e7alo Luzes","family":"Padeira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Isabel","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Freixo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina Greg\u00f3rio","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Farela","family":"Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-018-0570-1","article-title":"Molecular Mechanisms of EBV-Driven Cell Cycle Progression and Oncogenesis","volume":"208","author":"Yin","year":"2019","journal-title":"Med Microbiol Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161846","article-title":"Human Immunity Against EBV-Lessons From the Clinic","volume":"214","author":"Tangye","year":"2017","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000928","article-title":"Primary Immunodeficiencies Reveal the Molecular Requirements for Effective Host Defense Against EBV Infection","volume":"135","author":"Tangye","year":"2020","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00596-6","article-title":"Ebv-Related Hodgkin Lymphoma in an ICF2 Patient: is Ebv Susceptibility a Hallmark of This Icf Subtype","volume":"39","author":"Licciardi","year":"2019","journal-title":"J Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"(11)","DOI":"10.1084\/jem.20192262","article-title":"Rapid Identification and Characterization of Infected Cells in Blood During Chronic Active Epstein-Barr Virus Infection","volume":"217","author":"Fournier","year":"2020","journal-title":"J Exp Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/diseases7020034","article-title":"Progressive Immunodeficiency With Gradual Depletion of B and CD4\u207a T Cells in Immunodeficiency, Centromeric Instability and Facial Anomalies Syndrome 2 (Icf2)","volume":"7","author":"Sogkas","year":"2019","journal-title":"Dis (Basel Switzerland)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"7870","DOI":"10.1038\/ncomms8870","article-title":"Mutations in CDCA7 and HELLS Cause Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome","volume":"6","author":"Thijssen","year":"2015","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2016.18","article-title":"Downregulation of ZBTB24 Hampers the G0\/1- to S-Phase Cell-Cycle Transition Via Upregulating the Expression of IRF-4 in Human B Cells","author":"Liang","year":"2017","journal-title":"Genes Immun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0240-2","article-title":"Genetic, Cellular and Clinical Features of ICF Syndrome: A French National Survey","volume":"36","author":"Sterlin","year":"2016","journal-title":"J Clin Immunol;"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0559-y","article-title":"Clinical and Immunological Characterization of ICF Syndrome in Japan","volume":"38","author":"Kamae","year":"2018","journal-title":"J Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001210","article-title":"Hematopoietic Stem Cell Transplantation in a Patient With ICF2 Syndrome Presenting With EBV-Induced Hemophagocytic Lymphohystiocytosis","volume":"100","author":"Harnisch","year":"2016","journal-title":"Transplantation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaip.2019.08.040","article-title":"Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome With NK Dysfunction and EBV-Driven Malignancy Treated With Stem Cell Transplantation","volume":"8","author":"Burk","year":"2020","journal-title":"J Allergy Clin Immunol In Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.17.1.364","article-title":"Host-Cell-Determined Methylation of Specific Epstein-Barr Virus Promoters Regulates the Choice Between Distinct Viral Latency Programs","volume":"17","author":"Schaefer","year":"1997","journal-title":"Mol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"00225-6","DOI":"10.1016\/j.jaci.2021.01.035","article-title":"What Can Clinical Immunology Learn From Inborn Errors of Epigenetic Regulators","author":"Camacho-Ordonez","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5500\/wjt.v10.i2.29","article-title":"Post-Transplantation Lymphoproliferative Disorders: Current Concepts and Future Therapeutic Approaches","volume":"10","author":"Abbas","year":"2020","journal-title":"World J Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23786","article-title":"A Functional Assay to Classify ZBTB24 Missense Variants of Unknown Significance","volume":"40","author":"Wu","year":"2019","journal-title":"Hum Mutat"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.654167\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T06:50:58Z","timestamp":1619592658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.654167\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":16,"alternative-id":["10.3389\/fimmu.2021.654167"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.654167","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"article-number":"654167"}}